Holen Sie sich die Stockscreener-App
124.99
2.88%
-3.70
Handel nachbörslich:
124.36
-0.63
-0.50%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc. Stock Analysis and ForecastDynamic capital growth - Jammu Links News
Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Hold" by Analysts - MarketBeat
What drives Biogen Inc. stock priceRapid wealth creation - Jammu Links News
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know - Yahoo Finance
Here's What to Expect From Biogen's Next Earnings Report - MSN
Biogen’s New Study on Felzartamab: A Potential Game-Changer for IgAN Treatment - TipRanks
Here's What To Expect From Biogen's Next Earnings Report - Barchart.com
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Leo Wealth LLC - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires 736,301 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire
Biogen’s Innovative Approach to SMA Treatment: The PIERRE-PK Study - TipRanks
Biogen’s Spinraza Study: Real-World Insights and Market Impact - TipRanks
Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors - TipRanks
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection - TipRanks
Düsseldorf court to hear Tecfidera PI appeal as Biogen fights to stop generics - JUVE Patent
What is William Blair's Estimate for Biogen Q3 Earnings? - MarketBeat
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Biogen Inc. (NASDAQ:BIIB) Stock Position Reduced by Massachusetts Financial Services Co. MA - MarketBeat
Wedbush Forecasts Biogen's Q2 Earnings (NASDAQ:BIIB) - MarketBeat
Cwm LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
New York State Common Retirement Fund Acquires 20,130 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Alps Advisors Inc. Purchases Shares of 2,500 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cerity Partners LLC Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FY2025 EPS Estimates for Biogen Decreased by Leerink Partnrs - MarketBeat
Biogen Executive Makes Significant Stock Sale - TipRanks
Insider Selling: Biogen Inc. (NASDAQ:BIIB) Insider Sells 2,223 Shares of Stock - MarketBeat
Brown Advisory Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: Market Implications - TipRanks
Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB) - MarketBeat
Orphan Drugs Market Expansion Fueled by Rare Disease Research - openPR.com
William Blair Has Optimistic Outlook of Biogen Q2 Earnings - MarketBeat
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
State of Michigan Retirement System Has $5.43 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Stock Quote & Chart - Biogen
Erythromelalgia Treatment Market Growing with Rare Disease - openPR.com
Wedbush Raises Price Target on Biogen to $129 From $121, Keeps Neutral Rating - MarketScreener
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - GlobeNewswire Inc.
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights - TipRanks
SMN1 Gene Replacement Market 2025: Increasing SMA Population - openPR.com
Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com
Nisa Investment Advisors LLC Cuts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Holdings Cut by Greenleaf Trust - MarketBeat
M&T Bank Corp Has $1.68 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
When (BIIB) Moves Investors should Listen - news.stocktradersdaily.com
Banque Pictet & Cie SA Purchases 4,780 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of New York Mellon Corp Decreases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com
HSBC Raises Price Target on Biogen to $144 From $121, Maintains Hold Rating - MarketScreener
Biogen Inc.'s (NASDAQ:BIIB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - 富途牛牛
JPMorgan maintains Neutral rating on Biogen stock amid gradual Leqembi ramp - Investing.com Nigeria
Case builds for Biogen, Stoke's Dravet syndrome drug - pharmaphorum
Allspring Global Investments Holdings LLC Has $1.43 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer? - TipRanks
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Insider Monkey
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):